Literature DB >> 9295034

Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system.

H Körner1, F A Lemckert, G Chaudhri, S Etteldorf, J D Sedgwick.   

Abstract

Recently, we demonstrated that experimental autoimmune encephalomyelitis (EAE) in the rat, passively transferred using myelin basic protein (MBP)-reactive encephalitogenic CD4+ T cells, was preventable by administration of a p55-tumor necrosis factor-IgG fusion protein (TNFR-IgG). This was despite quantitatively and qualitatively normal movement of these MBP-specific T cells to the central nervous system (CNS). To extend these findings, the effect of TNFR-IgG on EAE actively induced by injection of MBP in complete Freund's adjuvant was examined. This form of EAE in the rat typically involves an acute, self-limiting neurological deficit, substantial CNS inflammation, but minimal demyelination. Here we show that administration of TNFR-IgG prior to onset of disease signs completely prevented the neurological deficit or markedly reduced its severity. This blockade of clinical disease was dissociated from weight loss which occurred at the same tempo and magnitude as in control rats exhibiting neurological signs of disease such as paralysis. The timing of TNF blockade was critical as established clinical disease was relatively refractory to TNFR-IgG treatment. Activated CD4+ T cells expressing normal or elevated levels of VLA4, major histocompatibility complex class II, MRC OX40 and CD25 were isolated from or immunohistochemically localized in the CNS of clinically healthy rats treated before disease onset. There was a reduction of the amount of other inflammatory leukocytes in the CNS of these treated animals but, more importantly, the activation state of inflammatory leukocytes, as well as that of microglia isolated from treated animals, was reduced. Thus, TNFR-IgG, when administered before disease onset, appears to act by inhibiting an effector function of activated T cells and possibly other inflammatory leukocytes necessary to bring about the neurological deficit. However, while TNF is a critically important cytokine for the early events leading to initiation of EAE, it is not a necessary factor in the acute neurological deficit characteristic of this form of EAE, once disease onset has occurred.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9295034     DOI: 10.1002/eji.1830270822

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  24 in total

1.  A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT.

Authors:  Jennifer L Gommerman; Keith Giza; Stuart Perper; Irene Sizing; Apinya Ngam-Ek; Cheryl Nickerson-Nutter; Jeffrey L Browning
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 2.  Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.

Authors:  Tjalf Ziemssen
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

3.  Astrocytes promote TNF-mediated toxicity to oligodendrocyte precursors.

Authors:  Sunja Kim; Andrew J Steelman; Hisami Koito; Jianrong Li
Journal:  J Neurochem       Date:  2010-12-02       Impact factor: 5.372

4.  Elevated interferon gamma expression in the central nervous system of tumour necrosis factor receptor 1-deficient mice with experimental autoimmune encephalomyelitis.

Authors:  Rachel D Wheeler; Simone P Zehntner; Lisa M Kelly; Lyne Bourbonnière; Trevor Owens
Journal:  Immunology       Date:  2006-06-16       Impact factor: 7.397

Review 5.  A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.

Authors:  Prabhakaran Kumar; Palash Bhattacharya; Bellur S Prabhakar
Journal:  J Autoimmun       Date:  2018-08-31       Impact factor: 7.094

6.  Interferon-gamma receptor-mediated but not tumor necrosis factor receptor type 1- or type 2-mediated signaling is crucial for the activation of cerebral blood vessel endothelial cells and microglia in murine Toxoplasma encephalitis.

Authors:  M Deckert-Schlüter; H Bluethmann; N Kaefer; A Rang; D Schlüter
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

Review 7.  Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines.

Authors:  Eugene Y Kim; Kamal D Moudgil
Journal:  Cytokine       Date:  2017-04-25       Impact factor: 3.861

Review 8.  Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis.

Authors:  Tanuja Chitnis; Samia J Khoury
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

9.  Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice.

Authors:  Katerina Akassoglou; Eleni Douni; Jan Bauer; Hans Lassmann; George Kollias; Lesley Probert
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-09       Impact factor: 11.205

10.  What can we learn from failed clinical trials in multiple sclerosis?

Authors:  Tjalf Ziemssen
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.